This article is from the source 'bbc' and was first published or seen on . It will not be checked again for changes.
You can find the current article at its original source at http://news.bbc.co.uk/go/rss/-/1/hi/health/7209470.stm
The article has changed 2 times. There is an RSS feed of changes available.
Previous version
1
Next version
Version 0 | Version 1 |
---|---|
UK patients to get new HIV drug | UK patients to get new HIV drug |
(about 8 hours later) | |
The first in a new class of HIV drugs has become available in the UK. | The first in a new class of HIV drugs has become available in the UK. |
It means doctors will have a further treatment option for patients who have built up resistance to existing drugs. | It means doctors will have a further treatment option for patients who have built up resistance to existing drugs. |
Raltegravir is an integrase inhibitor, which works by blocking an enzyme essential for HIV to be able to replicate itself. | Raltegravir is an integrase inhibitor, which works by blocking an enzyme essential for HIV to be able to replicate itself. |
An estimated 73,000 people live with HIV in the UK. Raltegravir will be reserved for those who have stopped responding to other treatment. | |
Resistance to HIV medication is becoming increasingly common - more than one in 10 UK patients with HIV has some level of resistance to at least one drug before they have even begun therapy, research has shown. | Resistance to HIV medication is becoming increasingly common - more than one in 10 UK patients with HIV has some level of resistance to at least one drug before they have even begun therapy, research has shown. |
A clinical trial of Raltegravir published last year found it to be effective in patients who had been taking regular antiretroviral HIV drugs for about 10 years. | |
The more ways we have to attack the virus, the more chance we have of successfully managing the disease Dr Mark Nelson, Chelsea and Westminster Hospital | The more ways we have to attack the virus, the more chance we have of successfully managing the disease Dr Mark Nelson, Chelsea and Westminster Hospital |
Treatment for HIV is helping people to live longer but, in the UK, one of the biggest challenges is the threat of resistance. | Treatment for HIV is helping people to live longer but, in the UK, one of the biggest challenges is the threat of resistance. |
Integrase is one of three HIV enzymes the virus uses to multiply. | Integrase is one of three HIV enzymes the virus uses to multiply. |
It inserts viral genes into the DNA of the host cell, effectively making it a "factory" for producing more of the virus. | It inserts viral genes into the DNA of the host cell, effectively making it a "factory" for producing more of the virus. |
Without this, the virus cannot multiply and infect other cells as easily, reducing the amount of virus present in the blood. | Without this, the virus cannot multiply and infect other cells as easily, reducing the amount of virus present in the blood. |
Mutation | Mutation |
Dr Mark Nelson, director of HIV services, at Chelsea and Westminster Hospital, London, said the drug would be used in a small proportion of patients as part of a combination of drugs. | Dr Mark Nelson, director of HIV services, at Chelsea and Westminster Hospital, London, said the drug would be used in a small proportion of patients as part of a combination of drugs. |
"HIV is a clever virus which adapts and mutates quickly, producing drug resistant strains of the virus. | "HIV is a clever virus which adapts and mutates quickly, producing drug resistant strains of the virus. |
"The more ways we have to attack the virus, the more chance we have of successfully managing the disease. | "The more ways we have to attack the virus, the more chance we have of successfully managing the disease. |
"But we've got to be smart about how we use these new drugs - we don't want to repeat past mistakes where resistance arose from using single therapies." | "But we've got to be smart about how we use these new drugs - we don't want to repeat past mistakes where resistance arose from using single therapies." |
Roger Pebody, treatment advisor at the Terrence Higgins Trust, said the drug would be useful for as many as 10% of people currently on treatment. | Roger Pebody, treatment advisor at the Terrence Higgins Trust, said the drug would be useful for as many as 10% of people currently on treatment. |
"This is excellent news for people who are resistant to other HIV drugs. | "This is excellent news for people who are resistant to other HIV drugs. |
"A combination of drugs is used to stop HIV at different stages of the process of entering and destroying the body's immune cells. | "A combination of drugs is used to stop HIV at different stages of the process of entering and destroying the body's immune cells. |
"If someone becomes resistant to any of their drugs, their treatment needs to be changed, and drugs which work in innovative ways can make a real difference." | "If someone becomes resistant to any of their drugs, their treatment needs to be changed, and drugs which work in innovative ways can make a real difference." |
Professor David Back, an expert in pharmacology at the University of Liverpool said the drug would be "extremely useful" in some patients. | Professor David Back, an expert in pharmacology at the University of Liverpool said the drug would be "extremely useful" in some patients. |
"Patients are remaining healthy for an extended period of time and there is a percentage who will fail therapy." | "Patients are remaining healthy for an extended period of time and there is a percentage who will fail therapy." |
He added that, if patients became resistant to one drug within a class, they could be resistant to others within that class even if they had never taken them before. | He added that, if patients became resistant to one drug within a class, they could be resistant to others within that class even if they had never taken them before. |
"It provides another option." | "It provides another option." |
Previous version
1
Next version